Search the Newsreel

Illumina Q2 Earnings Call Highlights

Key Points Interested in Illumina, Inc.? Here are five stocks we like better. Illumina exceeded expectations in Q2: Revenue rose 9.5% year over year to $1.16 billion, while non-GAAP EPS increased 10% to $1.31. The company raised its 2026 revenue outlook to $4.60 billion–$4.64 …

Reliance (RS) After Earnings And A Strong Run, Is The Bull Case Already Priced In?

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Reliance earnings event puts recent performance in focus Reliance (RS) reported second quarter 2026 results, with sales of US$4,630 million and net income of …

ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift

ILMN Q2 Deep Dive: Clinical Strength, Platform Expansion, and Strategic Focus Drive Guidance Lift Genomics company Illumina (NASDAQ:ILMN) beat Wall Street's revenue expectations in Q2 CY2026, with sales up 9.4% year on year to $1.16 billion. The company's full-year revenue guidance of $4.62 billion …

Century Aluminum (CENX) Could Be 39% Undervalued If Its Growth Narrative Holds

Century Aluminum (CENX) has shown strong longer-term returns despite recent volatility, with its share price at $44.88. A common narrative suggests the stock is 39.4% undervalued, with a fair value of $74 per share, driven by anticipated growth from the Mt. Holly expansion and …

Illumina CEO on Genomic Sequencing Opportunities and AI

Illumina CEO Jacob Thaysen discusses the company's earnings, genomic medicine opportunities and the potential for artificial intelligence in life sciences on "Bloomberg The Close." View Comments

ALMS|Alumis Inc|Price:26.970|Chg%:-1.280

This article provides a comprehensive stock analysis of Alumis Inc (ALMS), highlighting its relatively healthy fundamentals, significant growth potential, and "Strong Buy" analyst rating with a high price target. It details the company's biopharmaceutical focus, including its pipeline of therapies for immune-mediated and neuroinflammatory …

Illumina, Inc. Stock 12‑Month Price Target Raised to $193.61, Implies 6% Downside

Illumina, Inc.'s average 12-month price target has been increased to $193.61 from $175.72 by 18 analysts, with forecasts ranging from $95 to $230 per share. This new target suggests a 6% potential downside based on the July 30 closing price. The consensus rating for …

ILLUMINA INC : BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $140 FROM $120

BofA Global Research has increased its price objective for Illumina Inc. (ILMN.O) shares. The new target price is set at $140, up from the previous $120. This adjustment indicates a more positive outlook from the research firm regarding Illumina's future stock performance.

Vanguard Capital Management (KALU) reports 5.1% Kaiser Aluminum ownership in 13G

Vanguard Capital Management LLC has disclosed a 5.1% ownership stake in Kaiser Aluminum Corp (KALU), totaling 833,479 shares as of June 30, 2026. This Schedule 13G filing indicates Vanguard holds sole voting power over 126,318 shares and sole dispositive power over all 833,479 shares. …

Are Industrial Products Stocks Lagging Kaiser Aluminum (KALU) This Year?

Kaiser Aluminum (KALU) has outperformed its Industrial Products peers this year, gaining 39.1% compared to the sector's average of 14.5%. The company holds a Zacks Rank #1 (Strong Buy), with its full-year earnings consensus estimate increasing by 22.3% over the last three months. UniFirst …

Guggenheim eleva el precio objetivo de Illumina tras superar las previsiones de resultados

ILMN|Illumina Inc|Price:192.733|Chg%:-0.176

National Aluminium Company shares rise 2.06%

Vedanta Aluminium share price targets: Buy VAML stock, says Citi, Investec, Nuvama, MOFSL, Emkay post Q1 results

Illumina (ILMN) Stock Climbs On Clinical Growth Despite Margin Pressure

Illumina, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ILMN) 2026-07-31

Illumina (ILMN) reported strong Q2 2026 earnings with revenue up 9.4% to $1.16 billion, exceeding analyst expectations. Gross profit increased to $770 million, and diluted earnings per share were $1.35 against an expectation of $1.25, leading to a 3.86% rise in the company's stock …

ILMN|Illumina Inc|Price:191.209|Chg%:+3.249

Illumina Inc (ILMN) (Q2 2026) Earnings Call Highlights: Strong Clinical Growth Drives Revenue ...

This article first appeared on GuruFocus. Revenue: $1.16 billion in Q2 2026, up 9.5% year-over-year and 6.5% on an organic basis. Rest of World Organic Revenue Growth: 8.1% in Q2, above the high end of guidance. Sequencing Consumables Revenue: $775 million, up 5% year-over-year …

Reliance (RS) Could Be 4% Overvalued As Strong Q2 Earnings Draw Fresh Attention

Illumina Earnings: Strong Instrument Sales and Growing AI Opportunities Boost 2026 Outlook

Illumina Looks Likely To Benefit From AI Initiatives in Life Sciences

Illumina is expected to gain from the growing integration of AI in life sciences, as highlighted by strong instrument sales and increasing AI opportunities boosting its 2026 outlook. The company's strategy involves leading genomic sequencing through innovation and acquisitions, addressing broad applications from population …

Illumina (NASDAQ:ILMN) Surprises With Q2 CY2026 Sales, Full-Year Outlook Slightly Exceeds Expectations

Illumina (NASDAQ:ILMN) reported strong Q2 CY2026 results, with revenue of $1.16 billion exceeding analyst expectations and sales up 9.4% year-on-year. The company also raised its full-year revenue guidance to $4.62 billion and adjusted EPS guidance to $5.35 at the midpoint, both slightly above analyst …

Illumina’s 43% quarter meets a 58% Fair Value premium and thin volume near the high

Illumina closed at $194.10, only 2.5% below its 52-week high, but the latest 4.0% advance came on 0.8x 13-week average volume.

Earnings Flash (ILMN) Illumina, Inc. Posts Q2 Adjusted EPS $1.31 per Share, vs. FactSet Est of $1.23

Illumina, Inc. (ILMN) announced its Q2 adjusted EPS of $1.31 per share, surpassing FactSet’s estimate of $1.23. The company also reported Q2 revenue of $1.16 billion, exceeding FactSet's estimate of $1.13 billion, and provided earnings guidance for fiscal year 2026. The news highlighted the …

Earnings Flash (ILMN) Illumina, Inc. Reports Q2 Revenue $1.16B, vs. FactSet Est of $1.13B

Illumina, Inc. (ILMN) reported its second-quarter revenue at $1.16 billion, surpassing FactSet's estimate of $1.13 billion. The company specializes in DNA sequencing and array-based technologies for research, clinical, and applied markets, with products used in life sciences, oncology, reproductive health, and agriculture. Illumina also …

Illumina Reports Financial Results for Second Quarter of Fiscal Year 2026

SAN DIEGO, July 30, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the second quarter of fiscal year 2026. Second quarter 2026 results Revenue of $1.16 billion for Q2 2026, up 9.5% from Q2 2025 …

Illumina, Inc. (Nasdaq: ILMN) lifts 2026 outlook after Q2 revenue hits $1.16B

Illumina, Inc. (Nasdaq: ILMN) reported strong Q2 2026 financial results with revenue reaching $1.16 billion, a 9.5% increase from the previous year. This performance led the company to raise its full-year 2026 revenue guidance to $4.60-$4.64 billion and non-GAAP diluted EPS guidance to $5.30-$5.40. …

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) saw its stock rise by 5.27% to $205.09 on Thursday, contributing to its third consecutive day of gains. This performance outpaced the broader market, which also experienced a strong trading day with the S&P 500 Index rising 1.66% and the Dow …

Kaiser Aluminum Corporation (NASDAQ:KALU) Receives Consensus Recommendation of "Hold" from Analysts

Kaiser Aluminum Corporation (NASDAQ:KALU) has received a consensus "Hold" rating from analysts, with an average 12-month target price of $168.25. The company recently reported strong quarterly earnings of $5.53 EPS, significantly exceeding estimates, with revenue up 52.7% year-over-year. Kaiser Aluminum also declared a quarterly …

Illumination Acquisition Corp I Revenue Breakdown – NASDAQ:ILLU

This page provides a financial overview of Illumination Acquisition Corp I (ILLU) on Nasdaq. It highlights sections for financials, news, community, technical analysis, and ETFs, allowing users to explore fundamental statistics, statements, dividends, earnings, and segment performance.

Kaiser Aluminum Corporation $KALU Position Trimmed by Arrowstreet Capital Limited Partnership

Arrowstreet Capital Limited Partnership reduced its stake in Kaiser Aluminum Corporation (NASDAQ:KALU) by 8.6% in the first quarter, selling 23,340 shares. Despite this, other major institutional investors like Vanguard Group Inc., State Street Corp, and Dimensional Fund Advisors LP increased their holdings in the …

Century Aluminum (CENX) to Release Earnings on Thursday

Should Value Investors Buy Kaiser Aluminum (KALU) Stock?

Vedanta Aluminium Q1 PAT up threefold to `6,597 crore

VAML Q1 Profit Jumps 3x to ₹6,597 Cr After Demerger

Vedanta Aluminium Metal declares ₹8 interim dividend for FY2026-27